Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation

被引:50
作者
Bank, U
Küpper, B
Reinhold, D
Hoffmann, T
Ansorge, S
机构
[1] Otto Von Guericke Univ, Ctr Internal Med, Inst Immunol, D-39120 Magdeburg, Germany
[2] Otto Von Guericke Univ, Ctr Internal Med, Inst Expt Internal Med, D-39120 Magdeburg, Germany
[3] Probiodrug, D-06120 Halle, Germany
来源
FEBS LETTERS | 1999年 / 461卷 / 03期
关键词
D O I
10.1016/S0014-5793(99)01466-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The bioactivity of interleukin-6 (IL-6) was found to be dramatically reduced in fluids from sites of inflammation, Here, we provide evidence that the neutrophil-derived serine proteases elastase, proteinase 3 and cathepsin G are mainly involved in its degradation and subsequent inactivation. The initially hydrolyzed peptide bonds were detected to be Val(11)-Ala(12) and Leu(19)-Thr(20) (elastase), Phe(78)-Asn(79) (cathepsin G) and Ala(145)-Ser(146) (proteinase 3), The soluble IL-6 receptor elicits a protective effect against the IL-6 inactivation by cathepsin G only. The inactivation of IL-6 by neutrophil-derived serine proteases might act as a feedback mechanism terminating the IL-6-induced activation of neutrophils. (C) 1999 Federation of European Biochemical Societies.
引用
收藏
页码:235 / 240
页数:6
相关论文
共 40 条
  • [31] IN-VITRO PROCESSING OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA
    ROBACHEGALLEA, S
    MORAND, V
    BRUNEAU, JM
    SCHOOT, B
    TAGAT, E
    REALO, E
    CHOUAIB, S
    ROMANROMAN, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) : 23688 - 23692
  • [32] SALVESEN GS, 1999, HDB PROTEOLYTIC ENZY, pCH16
  • [33] CATHEPSIN-G AND LEUKOCYTE ELASTASE INACTIVATE HUMAN TUMOR-NECROSIS-FACTOR AND LYMPHOTOXIN
    SCUDERI, P
    NEZ, PA
    DUERR, ML
    WONG, BJ
    VALDEZ, CM
    [J]. CELLULAR IMMUNOLOGY, 1991, 135 (02) : 299 - 313
  • [34] Sehgal PB, 1996, P SOC EXP BIOL MED, V213, P238
  • [35] SUBCELLULAR-LOCALIZATION AND DYNAMICS OF MAC-1 (ALPHA(M)BETA(2)) IN HUMAN NEUTROPHILS
    SENGELOV, H
    KJELDSEN, L
    DIAMOND, MS
    SPRINGER, TA
    BORREGAARD, N
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (03) : 1467 - 1476
  • [36] SIRONI M, 1989, J IMMUNOL, V142, P549
  • [37] 1.9 angstrom crystal structure of interleukin 6: Implications for a novel mode of receptor dimerization and signaling
    Somers, W
    Stahl, M
    Seehra, JS
    [J]. EMBO JOURNAL, 1997, 16 (05) : 989 - 997
  • [38] IL-6 and APPs: anti-inflammatory and immunosuppressive mediators
    Tilg, H
    Dinarello, CA
    Mier, LW
    [J]. IMMUNOLOGY TODAY, 1997, 18 (09): : 428 - 432
  • [39] Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity
    Toniatti, C
    Cabibbo, A
    Sporeno, E
    Salvati, AL
    Cerretani, M
    Serafini, S
    Lahm, A
    Cortese, R
    Ciliberto, G
    [J]. EMBO JOURNAL, 1996, 15 (11) : 2726 - 2737
  • [40] PATHOLOGICAL CONCENTRATIONS OF INTERLEUKIN-6 INHIBIT T-CELL RESPONSES VIA INDUCTION OF ACTIVATION OF TGF-BETA
    ZHOU, DH
    MUNSTER, A
    WINCHURCH, RA
    [J]. FASEB JOURNAL, 1991, 5 (11) : 2582 - 2585